237 related articles for article (PubMed ID: 25906832)
1. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.
Wood BL
Cytometry B Clin Cytom; 2016 Jan; 90(1):47-53. PubMed ID: 25906832
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
3. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.
Oldaker TA; Wallace PK; Barnett D
Cytometry B Clin Cytom; 2016 Jan; 90(1):40-6. PubMed ID: 26201282
[TBL] [Abstract][Full Text] [Related]
5. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
Gormley NJ; Turley DM; Dickey JS; Farrell AT; Reaman GH; Stafford E; Carrington L; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):73-80. PubMed ID: 26108351
[TBL] [Abstract][Full Text] [Related]
6. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
Rawstron AC; de Tute RM; Haughton J; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease studies by flow cytometry in acute leukemia.
Campana D; Coustan-Smith E
Acta Haematol; 2004; 112(1-2):8-15. PubMed ID: 15178999
[TBL] [Abstract][Full Text] [Related]
8. One tube with eight antibodies for 14-part bone marrow leukocyte differential using flow cytometry.
Jacob MC; Souvignet A; Pont J; Solly F; Mondet J; Kesr S; Pernollet M; Dumestre-Perard C; Campos L; Cesbron JY
Cytometry B Clin Cytom; 2017 Jul; 92(4):299-309. PubMed ID: 26990701
[TBL] [Abstract][Full Text] [Related]
9. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
Stetler-Stevenson M; Paiva B; Stoolman L; Lin P; Jorgensen JL; Orfao A; Van Dongen J; Rawstron AC
Cytometry B Clin Cytom; 2016 Jan; 90(1):26-30. PubMed ID: 25907102
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
11. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
[TBL] [Abstract][Full Text] [Related]
13. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric determination of leukemia-associated marker combinations for the study of minimal residual disease.
Babusíková O; Glasová M; Kusenda J; Koníková E; Mésárosová A
Neoplasma; 1994; 41(6):305-13. PubMed ID: 7870213
[TBL] [Abstract][Full Text] [Related]
15. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
Rawstron AC; Paiva B; Stetler-Stevenson M
Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
[TBL] [Abstract][Full Text] [Related]
16. Recent advancements of flow cytometry: new applications in hematology and oncology.
Woo J; Baumann A; Arguello V
Expert Rev Mol Diagn; 2014 Jan; 14(1):67-81. PubMed ID: 24308362
[TBL] [Abstract][Full Text] [Related]
17. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
18. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
Campana D; Coustan-Smith E
Best Pract Res Clin Haematol; 2002 Mar; 15(1):1-19. PubMed ID: 11987913
[TBL] [Abstract][Full Text] [Related]
19. Technical issues: flow cytometry and rare event analysis.
Hedley BD; Keeney M
Int J Lab Hematol; 2013 Jun; 35(3):344-50. PubMed ID: 23590661
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
